←LLYEli Lilly and CompanyOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Eli Lilly leads in obesity drugs

Mounjaro

for diabetes

Zepbound

for obesity

Foundayo

its new pill

Tirzepatide acts on two gut hormones and is sold as Mounjaro for diabetes and Zepbound for obesity. Lilly now also sells a pill, Foundayo, against Novo Nordisk's drugs.

The company · 2 · What exactly does it sell?

One molecule is two thirds of sales

Each $1 of sales, second quarter of 2026
65%15%11%6%3%
Mounjaro and ZepboundOther diabetes and heartCancerImmune diseasesBrain and other

Everything else Lilly sells together is about a third.

The company · 3 · How does it make money?

Insurers and governments pay for weekly shots

$24.4Bsales last quarter
83.9%kept per $1 after making it
$16.71of tirzepatide a quarter per person

Insurers and governments decide how many patients are covered and at what price.

Is it a good business? · 4 · What gives it an edge?

A strong patent, with a date on it

13 May 2036

US patent end for tirzepatide

2037 and 2040

Europe and Japan

+48%

Lilly's growth, Novo flat to down

Novo has conceded both US prescription leads to Lilly.

Is it a good business? · 5 · What is the catch?

Novo still leads the obesity pill

Novo Nordisklaunched its pill first
CVSdropped Zepbound for its patients
Pfizerbuilding its own obesity drugs

Listed rivals: NVO · CVS · PFE

Insurers can switch all their patients at once, as CVS showed.

Is it a good business? · 6 · What does its record show?

Sales more than doubled, profit widened

Sales, $B
28.3
28.5
34.1
45.0
65.2
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales$28.3B → $65.2Bsales, 2021 to 2025
Kept74% → 83%kept per $1 after making it
Profit20% → 32%net profit per $1

Factories are bought ahead of volume, so capital spending per dollar more than doubled.

Is it a good business? · 7 · How much room is there to grow?

The limit is who pays, not patients

890 millionadults with obesity, WHO, 2022
40.3%the US obesity rate

Patients are plentiful; insurers and governments decide how many are treated and at what price.

Is it a good business? · 8 · Who is in charge?

A long-serving chief and research head

2017David Ricks became chief executive
2018Daniel Skovronsky took over research
Lucas Montarcethe third finance chief since 2021

Insiders own almost none of the company, and the finance seat keeps changing.

The story right now · 9 · Why are obesity drugs so big?

Weekly shots that cut weight sharply

+53%Lilly's volume growth
−15%lower prices
$91B to $92B2026 sales forecast

Drugs that mimic gut hormones help people lose weight. Patients are plentiful, so the question is how many of them insurers and governments will pay for.

The story right now · 10 · Can volume outrun price cuts?

More patients at lower prices

  1. Prices cut to widen access15% lower.
  2. Many more patientsVolume +53%.
  3. Sales still jump+39%.
  4. Coverage can endMedicare has a date.

Volume outran price cuts this year, but Medicare coverage has an end date and a rival won the pill's first year.

The story right now · 11 · What changed lately?

Sales up 39% and the forecast raised again

$24.4Bsales in the third quarter
$184Mof Foundayo, the pill
About $900Mof sales was one-off
2forecast raises this year

Strong quarter

Buyers paid no more for each dollar of sales than a year before, so the share rise was earned.

The story right now · 12 · What is everyone arguing about?

Has Lilly won obesity for good?

Many investors think

Lilly has won obesity and keeps compounding

We think

A rival won the pill, and coverage has an expiry date

The market has twice sold these shares hard on one setback and been wrong both times.

The price and our view · 13 · What is a share worth?

Cheaper than its history, still above our value

$943what we think a share is worth
$943our value
Attractive
below $754
Neutral
Unattractive
above $1,131
$433gloomy: growth halves, less kept per $1
$943our estimate: experts' path, then slowing
$1,326sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · What if it all works?

As a bet on its new drugs, it is fragile

Priced for successthe kind of bet this is
0.8×if it works
73%kept if it fails

Multiples of the company's value when the bet was last struck, 9 Nov 2026.

If the pill and retatrutide succeed, the shares are worth about what they cost, so the price already pays for success.

The price and our view · 15 · How could we be wrong?

One molecule carries the company

A generic challengeBiggest

On the one molecule.

Coverage with an end dateShowing now

Medicare.

Novo's pillWatch

Leads its first year.

Prices insurers payUnknown

Not disclosed.

Insurers can switch all their patients at once, as CVS showed.

The price and our view · 16 · How will we know?

February tests 2027 growth

Foundayo gains on Novo's pillGood sign
Volume keeps outrunning price cutsGood sign
Another insurer drops ZepboundBad sign
FEB 202712

Fourth-quarter and full-year 2026 results, 12 February. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 17 · So, what do we think?

The obesity leader, resting on one molecule

$943our value
Attractive
below $754
Neutral
Unattractive
above $1,131

UnattractiveMedium conviction

Mounjaro and Zepbound lead the obesity-drug market and sales grow very fast. But about two thirds of sales come from one molecule, Medicare coverage has an end date, and the price sits above even our sunny future.

↑ ↓ to move · C for contents